

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-23. (cancelled)

24. (previously presented) A complex for delivery and application of drugs to cells at their membranes comprising:

a parachute structure, having a preselected action diameter;

a therapeutic compound, being a photosensitizer;

wherein said parachute structure is two hydrophilic moieties attached to a branching unit, defining said preselected action diameter;

wherein said branching unit connects said hydrophilic moieties and said therapeutic compound and is selected from the group consisting of triazine trichloride and trimesinic acid trichloride;

wherein said photosensitizer is chosen from the group consisting of bacteriopheophorbide and pheophorbide; and

wherein said two hydrophilic moieties are glucosamines.

25. (currently amended) The complex according to claim 24, wherein said branching unit within said parachute structure is bonded to said photosensitizer through a spacer, wherein and said spacer is a molecule selected from the group consisting of beta-amino acids and gamma-amino butyric acid and is also bonded to said therapeutic compound, thus completing the connection between said branching unit and said therapeutic compound.

26. (currently amended) The complex according to claim 24, wherein said branching unit within said parachute structure is bonded to said photosensitizer through a spacer, wherein and said spacer is a molecule selected from the group consisting of poly-amino acids and an amino acid sequence and is also bonded to said therapeutic compound, thus completing said connection between said branching unit and said therapeutic compound.

27. (previously presented) The complex according to claim 26, wherein said amino acid sequence has an enzyme cleavable breaking point.

28. (previously presented) The complex according to claim 24, wherein said parachute structure is modified by a bonding of a Biotin at a C6 position of said glucosamine and then said Biotin is reacted with an Avidin-labeled tumor-specific antibody.
29. (previously presented) The complex according to claim 24, wherein said complex can be used to photochemically destroy cells, and wherein said cells are prokaryotic.
30. (previously presented) The complex according to claim 24, wherein said complex can be used to photochemically destroy cells, and wherein said cells are eukaryotic.
31. (previously presented) The complex according to claim 29, wherein said prokaryotic cells are bacteria.
32. (previously presented) The complex according to claim 30, wherein said eukaryotic cells are human/animal cells.
33. (currently amended) A method for the selective destruction of eukaryotic or prokaryotic cells comprising the steps of:
- a. administering the complex of claim 24 to a preselected tumor region within a patient;
 - b. waiting for a pretreatment time interval sufficient to allow said complex to localize at cell membranes within said tumor region; and
 - c. irradiating said tumor region for a defined treatment time interval and intensity to activate said photosensitizer; wherein said treatment time interval and intensity are sufficient to achieve destruction of cells within said tumor region.
34. (currently amended) A method for the selective destruction of eukaryotic or prokaryotic cells comprising the steps of:
- a. administering the complex of claim 25 to a preselected tumor region within a patient;
 - b. waiting for a pretreatment time interval sufficient to allow said complex to localize at cell membranes within said tumor region; and
 - c. irradiating said tumor region for a defined treatment time interval and intensity to activate said photosensitizer; wherein said treatment time interval and intensity are sufficient to achieve destruction of cells within said tumor region.